Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

著者: Evandro de Azambuja, Andrew Holmes, Martine Piccart, Eileen Holmes, Serena Di Cosimo, Ramona F. Swaby, Michael Untch, Christian Jackisch, István Láng, Ian Smith, Frances Boyle, Binghe Xu, Carlos H. Barrios, Edith A. Perez, Hatem A. Azim, Sung‐Bae Kim, Sherko Küemmel, Chiun‐Sheng Huang, Peter Vuylsteke, Ruey‐Kuen Hsieh, В. А. Горбунова, Alexandru Eniu, Lydia Dreosti, Natalia Tavartkiladze, Richard D. Gelber, Holger Eidtmann, José Baselga - The Lancet 2014 被引用: 455